Orthofix Medical (NASDAQ:OFIX) CEO Massimo Calafiore Sells 9,600 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,600 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $15.82, for a total transaction of $151,872.00. Following the completion of the sale, the chief executive officer owned 227,034 shares of the company’s stock, valued at $3,591,677.88. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Monday, January 12th, Massimo Calafiore sold 9,797 shares of Orthofix Medical stock. The shares were sold at an average price of $15.21, for a total value of $149,012.37.

Orthofix Medical Price Performance

Shares of OFIX stock traded down $0.44 during mid-day trading on Tuesday, reaching $14.81. The company’s stock had a trading volume of 187,589 shares, compared to its average volume of 227,586. The company has a market cap of $586.48 million, a P/E ratio of -4.89 and a beta of 0.79. The firm’s 50-day moving average is $15.39 and its two-hundred day moving average is $14.23. Orthofix Medical Inc. has a 1-year low of $10.24 and a 1-year high of $20.48. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Wednesday, October 8th. Barrington Research increased their target price on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Finally, Stifel Nicolaus initiated coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Institutional Trading of Orthofix Medical

Hedge funds have recently bought and sold shares of the business. CWM LLC raised its position in shares of Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 955 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of Orthofix Medical during the 3rd quarter worth $30,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Orthofix Medical in the 2nd quarter worth about $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Orthofix Medical by 32.6% in the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company’s stock worth $148,000 after buying an additional 3,271 shares during the last quarter. Finally, Mackenzie Financial Corp purchased a new position in Orthofix Medical in the 3rd quarter worth approximately $148,000. 89.76% of the stock is currently owned by institutional investors.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.